Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative RPS working group.Ann Surg. 2016; 263: 1002-1009
- Leiomyosarcoma.Hematol Oncol Clin North Am. 2013; 27: 957-974
- Soft tissue and uterine leiomyosarcoma.J Clin Oncol. 2018; 36: 144-150
- Malignant smooth muscle tumors of the retroperitoneum and mesentery: a clinicopathologic analysis of 44 cases.J Surg Oncol. 1985; 28: 177-186
Cancer IAfRo, editor. WHO classification of tumours of soft tissue and bone. 5 edition. Lyon (France)2020.
- Soft tissue sarcoma. Epidemiology and prognosis in 508 patients.Acta Orthop Scand Suppl. 1994; 259: 1-31
- Clinical management of uterine sarcomas.Lancet Oncol. 2009; 10: 1188-1198
- Gastrointestinal stromal tumors and leiomyosarcomas.J Surg Oncol. 2008; 97: 350-359
- Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group.Cancer. 2007; 109: 282-291
- Leiomyosarcomas of venous origin in the extremities. A correlated clinical, roentgenologic, and morphologic study with diagnostic and surgical implications.Cancer. 1984; 54: 2147-2159
- Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison.Ann Surg Oncol. 2001; 8: 290-299
- Predictors of survival and recurrence in primary leiomyosarcoma.Ann Surg Oncol. 2013; 20: 1851-1857
- Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients.Ann Surg. 1993; 217: 72-77
- Bone and soft-tissue sarcoma risk in long-term survivors of hereditary retinoblastoma treated with radiation.J Clin Oncol. 2019; 37: 3436-3445
- Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system.Int J Cancer. 1984; 33: 37-42
- Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival.Nat Commun. 2021; 12: 4496
- Integrative genomic and transcriptomic analysis of leiomyosarcoma.Nat Commun. 2018; 9: 144
- Comprehensive and integrated genomic characterization of adult soft tissue sarcomas.Cell. 2017; 171: 950-965 e28
- Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.Oncogene. 2010; 29: 845-854
- Oncogenic gene-expression programs in leiomyosarcoma and characterization of conventional, inflammatory, and uterogenic subtypes.Mol Cancer Res. 2020; 18: 1302-1314
- Principles in management of soft tissue sarcoma.Adv Surg. 2015; 49: 107-122
- Radiological imaging features of non-uterine leiomyosarcoma.Br J Radiol. 2008; 81: 73-81
- Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET.J Nucl Med. 2010; 51: 1174-1181
- Needle tract seeding following core biopsies in retroperitoneal sarcoma.Eur J Surg Oncol. 2017; 43: 1740-1745
- Early and late complications of percutaneous core needle biopsy of retroperitoneal tumors at two tertiary sarcoma centers.Ann Surg Oncol. 2019; 26: 4692-4698
- Management of primary retroperitoneal sarcoma (RPS) in the adult: an updated consensus approach from the Transatlantic Australasian RPS Working Group.Ann Surg Oncol. 2021; 28: 7873-7888
- Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: a multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group.Cancer. 2021; 127: 729-738
- Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.Cancer. 2020; 126: 2637-2647
- Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2020; 21: 1366-1377
- Surgical technique, morbidity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava.Ann Surg Oncol. 2012; 19: 511-518
- Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control.Ann Surg Oncol. 2010; 17: 1507-1514
- Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients.J Clin Oncol. 2009; 27: 24-30
- Postoperative morbidity after radical resection of primary retroperitoneal sarcoma: a report from the Transatlantic RPS Working Group.Ann Surg. 2018; 267: 959-964
- Outcome of iliocaval resection and reconstruction for retroperitoneal sarcoma.J Vasc Surg Venous Lymphat Disord. 2019; 7: 547-556
- Multidisciplinary management of oligometastatic soft tissue sarcoma.Am Soc Clin Oncol Educ Book. 2018; 38: 939-948
- Impact of surgery in patients with metastatic soft tissue sarcoma: a monocentric retrospective analysis.J Surg Oncol. 2018; 118: 167-176
- Histology-based classification predicts pattern of recurrence and improves risk stratification in primary retroperitoneal sarcoma.Ann Surg. 2016; 263: 593-600
- Uterine sarcomas.Int J Gynaecol Obstet. 2018; 143: 51-58
- Uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation.Gynecol Oncol. 2017; 145: 208-216
Martee L Hensley MML. Treatment and Prognosis of Uterine Leiomyosarcoma. UptoDate [Internet]. 2021.
Stewart EA. Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas. UptoDate [Internet]. 2021.
- The role of endometrial biopsy in the preoperative detection of uterine leiomyosarcoma.J Minim Invasive Gynecol. 2016; 23: 567-572
- A more accurate method to interpret lactate dehydrogenase (LDH) isoenzymes' results in patients with uterine masses.Eur J Obstet Gynecol Reprod Biol. 2019; 236: 143-147
National Comprehensive Cancer Network. Uterine Neoplasms. 2021. In: NCCN Clinical Practice Guidelines in Oncology [Internet].
- Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis.Gynecol Oncol. 2015; 137: 167-172
- Peritoneal washings after power morcellation in laparoscopic myomectomy: a pilot study.J Minim Invasive Gynecol. 2016; 23: 578-581
- Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: a Korean multicenter study.J Obstet Gynaecol Res. 2020; 46: 337-346
- Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study.Gynecol Oncol. 2017; 145: 61-70
- Secondary surgical resection for patients with recurrent uterine leiomyosarcoma.Gynecol Oncol. 2019; 154: 333-337
- Surgical and oncologic outcomes of hyperthermic intraperitoneal chemotherapy for uterine leiomyosarcoma: a systematic review of literature.Gynecol Oncol. 2021; 161: 70-77
- Treatment of soft tissue sarcoma: a focus on earlier stages.Future Oncol. 2017; 13: 13-21
- Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.Lancet Oncol. 2012; 13: 1045-1054
- Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.J Clin Oncol. 2001; 19: 1238-1247
- Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data.Lancet. 1997; 350: 1647-1654
- A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.Cancer. 2008; 113: 573-581
- Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.Ann Oncol. 2014; 25: 2425-2432
- NCCN guidelines insights: soft tissue sarcoma, version 1.2021.J Natl Compr Canc Netw. 2020; 18: 1604-1612
- Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.J Clin Oncol. 1999; 17: 150-157
- Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study.BMC Med. 2017; 15: 78
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.Lancet Oncol. 2014; 15: 415-423
- Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial.JAMA. 2020; 323: 1266-1276
- Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.Lancet Oncol. 2017; 18: 1397-1410
- Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.Lancet Oncol. 2017; 18: 1089-1103
- Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.Gynecol Oncol. 2008; 109: 323-328
- Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).Oncologist. 2012; 17: 1213-1220
- Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial.J Clin Oncol. 2016; 34: 786-793
- Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.Cancer. 2019; 125: 2610-2620
- Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.Lancet. 2016; 387: 1629-1637
- Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].J Clin Oncol. 2007; 25: 2755-2763
- Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.Gynecol Oncol. 2005; 96: 749-752
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.The Lancet. 2012; 379: 1879-1886
- Outcome of uterine sarcoma patients treated with pazopanib: a retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.Gynecol Oncol. 2016; 142: 89-94
- Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.Cancer. 2014; 120: 738-743
- Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.Gynecol Oncol. 2010; 116: 424-429
- Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study.Cancer. 2017; 123: 3285-3290
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.Lancet Oncol. 2017; 18: 1493-1501
- A retrospective analysis of the efficacy of immunotherapy in metastatic soft-tissue sarcomas.Cancers (Basel). 2020; 12
- Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.Lancet Oncol. 2018; 19: 416-426
- B cells are associated with survival and immunotherapy response in sarcoma.Nature. 2020; 577: 556-560
- Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).J Immunother Cancer. 2018; 6: 63
- Unmet medical needs and future perspectives for leiomyosarcoma patients-a position paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN).Cancers (Basel). 2021; 13
- Detection of circulating tumor DNA in patients with uterine leiomyomas.JCO Precis Oncol. 2019; 3
- Detection of circulating tumor DNA in patients with leiomyosarcoma with progressive disease.JCO Precis Oncol. 2019; 2019
- Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma.Clin Cancer Res. 2018; 24: 2688-2699
- Homologous recombination repair deficiency as a therapeutic target in sarcoma.Semin Oncol. 2020; 47: 380-389
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
